📈 Stocks / Finance

UniQure plunges 49% on FDA reversal for gene therapy

Investor’s Business Daily

UniQure shares fell 49.3% after the FDA reversed its stance on using Phase I/II data for AMT-130 approval, casting doubt on the Huntington’s therapy timeline. The stock erased prior gains and broke its 50-day line on volume, despite earlier 'game-changing' trial results.

Palantir beats earnings for ninth straight quarter, lifts 2025 forecast

Sherwood

Palantir reported Q3 EPS of $0.21 vs. $0.17 expected, with revenue up 63% to $1.18B. It raised full-year guidance to $4.396–$4.400B, well above Wall Street’s $4.139B. U.S. commercial sales surged 121%. Shares are up 150% YTD, following a 340% gain in 2024.

AI leaders lift S&P as broader market lags

PBS News

The S&P 500 edged up 0.2%, driven by gains in Nvidia (+2.2%) and Amazon (+4%) following major AI deals. Most stocks declined, with the Dow falling 226 points. Analysts warn valuations may be stretched as AI-driven momentum masks broader market weakness.

🪙 Crypto

$1.1B in crypto liquidations as Bitcoin, Ethereum plunge

Yahoo Finance

Over $1.1B in crypto positions were liquidated as Bitcoin dropped 4% to $105,699 and Ethereum fell 7% to $3,583. Altcoins saw sharper losses. Analysts cited weakened U.S. spot demand and a negative Coinbase premium, despite stocks like the Nasdaq staying green.

🌎 Global Economy

Rodrik calls for a reimagined, service-led global economy

The New Yorker

Harvard economist Dani Rodrik argues the post-Trump world must abandon hyperglobalization. He proposes a productivist model centered on inclusive growth via services, green energy, and experimental industrial policy—shifting power from global rules to domestic innovation.

The #1 AI Newsletter for Business Leaders

Join 400,000+ executives and professionals who trust The AI Report for daily, practical AI updates.

Built for business—not engineers—this newsletter delivers expert prompts, real-world use cases, and decision-ready insights.

No hype. No jargon. Just results.

Subscribe free—trusted by leaders